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background:  Recent AHA/ACC societal guidance documents endorsed the use of a 10-year atherosclerotic cardiovascular disease risk 
assessment (ASCVD score) for guidance of statin therapies. To date, the comparative ability of the ASCVD, Framingham risk score (FRS), 
or NCEP ATP III score to diagnose obstructive coronary artery disease (CAD) or prognostic future outcomes remains untested.
Methods:  From the multicenter international CONFIRM long-term registry (N=17,181), we included asymptomatic subjects with age of 20-
79 years without known CAD who underwent coronary computed tomographic angiography. We calculated ASCVD, FRS, and NCEP ATP 
III scores and evaluated their discriminatory value for obstructive CAD and prognostic benefit for all-cause mortality using C statistics.
Results:  The study population consisted of 1,096 asymptomatic subjects: 72% were male and mean age was 60 ± 9 years. Among 
the study population, 276 had obstructive CAD and 41 all-cause deaths were occurred during a mean follow-up of 4.9 ± 1.2 years. As 
demonstrated in Table 1, there was no difference among the methods for the discrimination of obstructive CAD. However, the ASCVD 
score demonstrated significantly improved discrimination for risk of future all-cause mortality.
conclusion:  The ASCVD risk estimation system demonstrated similar predictive power for determining the present obstructive CAD, but 
improved prognostic power for predicting long-term mortality than previous risk stratification methods.
 
